<DOC>
	<DOCNO>NCT00378833</DOCNO>
	<brief_summary>This 16-week clinical trial lipid clinic patient niacin therapy appropriate evaluate tolerability MK0524A versus niacin extended-release . There 6 schedule clinic visit 2 treatment group .</brief_summary>
	<brief_title>Tolerability MK0524A Versus Niacin Extended-Release ( 0524A-054 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Patient appropriate candidate niacin therapy ( risk heart disease ) triglycerides &lt; 500 mg/dL Patients history cardiovascular event directly link atherosclerosis low density lipoproteincholesterol ( LDLC ) &gt; /= 130 mg/dL and/or statin Patients diabetes LDLC &gt; /= 130 mg/dL . Patients &gt; /= 2 heart disease risk factor LDLC &gt; /= 160 mg/dL . Patients cardiovascular event ( e.g. , heart attack , stroke ) within previous 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Primary Hypercholesterolemia Mixed Hyperlipidemia</keyword>
</DOC>